XML 108 R35.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Collaborative Research and Development Agreements - Narrative (Details) |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Nov. 24, 2023 USD ($) | Oct. 23, 2020 USD ($) | Dec. 31, 2023 USD ($) | Mar. 31, 2014 | Dec. 31, 2022 USD ($) | Sep. 30, 2018 USD ($) | Dec. 31, 2023 USD ($) milestone | Dec. 31, 2022 USD ($) milestone | Dec. 31, 2021 USD ($) milestone
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  | $ 17,157,000 | $ 10,287,000 | $ 63,175,000
GSK |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  | 17,200,000 | 10,300,000 | 63,200,000
GSK | Collaborative Research and Development Agreement | Minimum |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Royalty percent on net sales |  |  |  | 4.00% |  |  |  |  |
GSK | Collaborative Research and Development Agreement | Maximum |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Royalty percent on net sales |  |  |  | 8.00% |  |  |  |  |
GSK | Collaborative Research and Development Agreement | Anti-PD-1 (Jemperli/Dostarlimab) |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Agreement term following first commercial sale or expiration of the last to expire patent (in years) |  | 12 years |  |  |  |  |  |  |
GSK | Phase 3 clinical trial initiation - first indication | Anti-PD-1 (Jemperli/Dostarlimab) |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  | $ 5,000,000.0 |  |  |
GSK | Phase 3 clinical trial initiation - first indication | Anti-TIM-3 (GSK4069889A/Cobolimab) |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  | $ 5,000,000.0 |  |  | $ 5,000,000 |
Number of milestones achieved during period | milestone |  |  |  |  |  |  |  | 1 |
GSK | Royalty Agreement |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  | 17,200,000 | $ 5,300,000 | 3,200,000
GSK | Royalty Agreement, up To $1. 0 billion | Anti-PD-1 (Jemperli/Dostarlimab) |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Royalty percent on net sales |  | 8.00% |  |  |  |  |  |  |
Royalty sales |  | $ 1,000,000,000 |  |  |  |  |  |  |
GSK | Royalty Agreement, above $1. 0 billion | Anti-PD-1 (Jemperli/Dostarlimab) |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Royalty sales |  | $ 1,000,000,000 |  |  |  |  |  |  |
GSK | Royalty Agreement, above $1. 0 billion | Anti-PD-1 (Jemperli/Dostarlimab) | Minimum |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Royalty percent on net sales |  | 12.00% |  |  |  |  |  |  |
GSK | Royalty Agreement, above $1. 0 billion | Anti-PD-1 (Jemperli/Dostarlimab) | Maximum |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Royalty percent on net sales |  | 25.00% |  |  |  |  |  |  |
GSK | JEMPERLI Royalty Monetization Agreement |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  | 13,800,000 | 2,300,000 |
Non cash royalty revenue, for sale of future royalties |  |  |  |  |  |  |  | 2,300,000 |
GSK | Zejula Revenue |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  | 1,600,000 |
GSK | Zejula Royalty Monetization Agreement |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  | 3,400,000 | 1,400,000 |
GSK | Milestone Agreements |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  | $ 0 | $ 5,000,000 | $ 60,000,000
Number of milestones achieved during period | milestone |  |  |  |  |  |  | 0 | 1 | 4
Centessa | Collaborative Research and Development Agreement |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Potential future payments | $ 10,000,000 |  | $ 10,000,000 |  |  |  | $ 10,000,000 |  |
Centessa | Collaborative Research and Development Agreement | License Agreement, Centessa Pharmaceuticals (UK) Limited |  |  |  |  |  |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |  |  |  |  |  |
Cash payment | 4,000,000 |  | 7,000,000 |  |  |  |  |  |
Reimbursement | $ 3,000,000 |  |  |  |  |  |  |  |
Transaction costs incurred |  |  | 300,000 |  |  |  |  |  |
Total transaction |  |  | $ 7,300,000 |  |  |  |  |  |

X
- Definition Asset Acquisition, Contingent Consideration Arrangements, Range of Outcomes, Value, High + References No definition available. + Details
Name: | anab_AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Net Sales Royalty, Percent + References No definition available. + Details
Name: | anab_NetSalesRoyaltyPercent
Namespace Prefix: | anab_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Net Sales Royalty Threshold + References No definition available. + Details
Name: | anab_NetSalesRoyaltyThreshold
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Noncash Advance Future Royalties Revenue + References No definition available. + Details
Name: | anab_NoncashAdvanceFutureRoyaltiesRevenue
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reimbursement Payments to Acquire Productive Assets + References No definition available. + Details
Name: | anab_ReimbursementPaymentsToAcquireProductiveAssets
Namespace Prefix: | anab_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue Recognition, Milestone Method, Commercial Sale Or Expiration Of Patents, Agreement Term + References No definition available. + Details
Name: | anab_RevenueRecognitionMilestoneMethodCommercialSaleOrExpirationOfPatentsAgreementTerm
Namespace Prefix: | anab_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period + References No definition available. + Details
Name: | anab_RevenueRecognitionMilestoneMethodNumberOfMilestonesAchievedDuringPeriod
Namespace Prefix: | anab_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction cost incurred as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=anab_GlaxoSmithKlineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiPD1JEMPERLIDostarlimabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_Phase3ClinicalTrialInitiationFirstIndicationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=anab_AnaptysBioGeneratedAntiTIM3GSK4069889ACobolimabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_RoyaltyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_RoyaltyAgreementUpTo10BillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_RoyaltyAgreementAbove10BillionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_JEMPERLIRoyaltyMonetizationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_ZejulaRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_ZejulaRoyaltyMonetizationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=anab_MilestoneAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=anab_CentessaPharmaceuticalsUKLimitedCentessaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=anab_LicenseAgreementCentessaPharmaceuticalsUKLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |